$1.98
▲ +$0.05
(+2.59%)
Vol 375K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$94.5M
ROE
-166.9%
Margin
-3133.9%
D/E
1.54
Beta
1.93
52W
$1–$3
Wall Street Consensus
9 analysts · Apr 20262
Strong Buy
5
Buy
2
Hold
0
Sell
0
Strong Sell
77.8%
Buy Rating
Price Chart
Similar Stocks
DTIL
Precision BioSciences Inc
$100.1M
FATE
Fate Therapeutics Inc
$113.3M
SPRO
Spero Therapeutics Inc
$131.3M
BDTX
Black Diamond Therapeutics Inc
P/E 6.4
$138.4M
KLRS
Kalaris Therapeutics Inc
$141.3M
AGEN
Agenus Inc
$106.8M
EQ
Equillium Inc
$94.4M
HUMA
Humacyte Inc
$185.4M
IMDX
Insight Molecular Diagnostics Inc
$215.0M
Earnings
Beat rate: 40.0%
Next Report
May 06, 2026
EPS Estimate: $-0.34
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.34 | — | — |
| Dec 2025 | $-0.44 | $-0.59 | $-0.15 |
| Sep 2025 | $-0.53 | $-0.44 | +$0.09 |
| Jun 2025 | $-0.71 | $-0.61 | +$0.10 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $1.7M | $1.2M | $1.0M | $933K | $615K |
| Net Income | -$180.0M | -$23.1M | -$46.9M | -$25.4M | -$23.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -321.5% | -203.5% | -321.4% | -321.4% | -321.5% | -166.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -2719.4% | -5787.3% | -5681.6% | -5681.6% | -5682.2% | -3133.9% |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| D/E Ratio | 1.70 | 0.90 | 1.70 | 1.70 | 1.70 | 1.54 |
| Current Ratio | 1.78 | 1.23 | 1.78 | 1.78 | 1.78 | 1.28 |
Key Ratios
ROA (TTM)
-34.9%
P/S (TTM)
24.90
P/B
0.9
EPS (TTM)
$-3.26
CF/Share
$-9.69
Rev Growth 3Y
-45.3%
52W High
$3.40
52W Low
$1.09
$1.09
52-Week Range
$3.40
Financial Health
Free Cash Flow
-$11.8M
Net Debt
$10.1M
Cash
$23.9M
Total Debt
$33.9M
As of Sep 30, 2025
How does CBUS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CBUS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
24.9
▲
94%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.9
▼
64%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CBUS profitability vs Biotechnology peers
ROE
-166.9%
▼
148%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-3133.9%
▼
993%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
100.0%
▲
27%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-34.9%
▲
25%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
CBUS financial health vs Biotechnology peers
D/E ratio
1.5
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
1.3
▼
71%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.9
▲
99%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CBUS fundamentals radar
CBUS
Peer median
Industry
CBUS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio